27 results on '"Boulay, I."'
Search Results
2. Machine learning-based spin structure detection
- Author
-
Labrie-Boulay, I., Winkler, T., Franzen, D., Romanova, A., Fangohr, H., and Kläui, M.
- Abstract
One of the most important magnetic spin structure is the topologically stabilised skyrmion quasi-particle. Its interesting physical properties make them candidates for memory and efficient neuromorphic computation schemes. For the device operation, detection of the position, shape, and size of skyrmions is required and magnetic imaging is typically employed. A frequently used technique is magneto-optical Kerr microscopy where depending on the samples material composition, temperature, material growing procedures, etc., the measurements suffer from noise, low-contrast, intensity gradients, or other optical artifacts. Conventional image analysis packages require manual treatment, and a more automatic solution is required. We report a convolutional neural network specifically designed for segmentation problems to detect the position and shape of skyrmions in our measurements. The network is tuned using selected techniques to optimize predictions and in particular the number of detected classes is found to govern the performance. The results of this study shows that a well-trained network is a viable method of automating data pre-processing in magnetic microscopy. The approach is easily extendable to other spin structures and other magnetic imaging methods.
- Published
- 2023
3. Influence of clinical suspicion on CT accuracy of acute mesenteric ischemia: Retrospective study of 362 patients
- Author
-
Anglaret, S., primary, Dallongeville, A., additional, Beaussier, H., additional, Touloupas, C., additional, Boulay, I., additional, Tardivel, A.M., additional, Béranger, S., additional, Silvera, S., additional, Chatellier, G., additional, Ronot, M., additional, and Zins, M., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Imaging features of nodular regenerative hyperplasia of the liver mimicking hepatic metastases
- Author
-
Clouet, M., Boulay, I., Boudiaf, M., Soyer, P., Nemeth, J., Kiselman, R., and Rymer, R.
- Published
- 1999
- Full Text
- View/download PDF
5. Nouvelles perspectives dans l’action paracrine et/ou endocrine des BMPs au niveau hypophysaire
- Author
-
Sallon, C., primary, Boulay, I., additional, Logeart-Avramoglou, D., additional, Fontaine, M.-J., additional, Canépa, S., additional, Cayla, X., additional, and Taragnat, C., additional
- Published
- 2013
- Full Text
- View/download PDF
6. Ureteral calculi: diagnostic efficacy of helical CT and implications for treatment of patients.
- Author
-
Boulay, I, primary, Holtz, P, additional, Foley, W D, additional, White, B, additional, and Begun, F P, additional
- Published
- 1999
- Full Text
- View/download PDF
7. Thrombose aiguë de l'artère tibiale antérieure au cours de la varicelle chez une immunodéprimée sous cyclosporine
- Author
-
Farge, D., primary, Ribaud, P., additional, Chanu, B., additional, Boulay, I., additional, Aractingi, S., additional, and Rouffy, J., additional
- Published
- 1992
- Full Text
- View/download PDF
8. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
- Author
-
Hager, K. J., Marc, G. Pdréz, Gobeil, P., Diaz, R. S., Heizer, G., Llapur, C., Makarkov, A. I., Vasconcellos, E., Pillet, S., Riera, F., Saxena, P., Wolff, P. Geller, Bhutada, K., Wallace, G., Aazami, H., jones, C. E., Polack, F. P., Ferrara, L., Atkins, J., and Boulay, I.
- Abstract
Background: Coronavirus-like particles (CoVLP) that are produced in plants and display the prefusion spike glycoprotein of the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are combined with an adjuvant (Adjuvant System 03 [AS03]) to form the candidate vaccine.Methods: In this phase 3, multinational, randomized, placebo-controlled trial conducted at 85 centers, we assigned adults (≥18 years of age) in a 1:1 ratio to receive two intramuscular injections of the CoVLP+AS03 vaccine or placebo 21 days apart. The primary objective of the trial was to determine the efficacy of the CoVLP+AS03 vaccine in preventing symptomatic coronavirus disease 2019 (Covid-19) beginning at least 7 days after the second injection, with the analysis performed after the detection of at least 160 cases.Results: A total of 24,141 volunteers participated in the trial; the median age of the participants was 29 years. Covid-19 was confirmed by polymerase-chain-reaction assay in 165 participants in the intention-to-treat population; all viral samples that could be sequenced contained variants of the original strain. Vaccine efficacy was 69.5% (95% confidence interval [CI], 56.7 to 78.8) against any symptomatic Covid-19 caused by five variants that were identified by sequencing. In a post hoc analysis, vaccine efficacy was 78.8% (95% CI, 55.8 to 90.8) against moderate-to-severe disease and 74.0% (95% CI, 62.1 to 82.5) among the participants who were seronegative at baseline. No severe cases of Covid-19 occurred in the vaccine group, in which the median viral load for breakthrough cases was lower than that in the placebo group by a factor of more than 100. Solicited adverse events were mostly mild or moderate and transient and were more frequent in the vaccine group than in the placebo group; local adverse events occurred in 92.3% and 45.5% of participants, respectively, and systemic adverse events in 87.3% and 65.0%. The incidence of unsolicited adverse events was similar in the two groups up to 21 days after each dose (22.7% and 20.4%) and from day 43 through day 201 (4.2% and 4.0%).Conclusions: The CoVLP+AS03 vaccine was effective in preventing Covid-19 caused by a spectrum of variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease. (Funded by Medicago; ClinicalTrials.gov number, NCT04636697.). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Engaging care partners of persons living with dementia in acceptance and commitment therapy (ACT) programs: a scoping review.
- Author
-
Durepos P, MacLean R, Ricketts N, Boamah SA, Witherspoon R, Gould O, Olthuis JV, Totton K, Tucker K, Boulay I, Robitaille A, Aquino-Russell C, and Kaasalainen S
- Subjects
- Humans, Depression therapy, Dementia therapy, Caregivers psychology, Acceptance and Commitment Therapy methods
- Abstract
Objectives: Acceptance and commitment therapy (ACT) is a relatively new type of psychotherapy effective for treating depression and anxiety amongst family care partners of persons living with dementia [PLWD]. However, care partner engagement in mental health services is low and specific guidelines for designing ACT programs for care partners of PLWD do not exist. The purpose of this scoping review was to examine patterns in care partner engagement in ACT programs to identify program factors potentially influencing engagement., Methods: A comprehensive scoping review according to Arksey and O'Malley's framework was followed. Databases and grey literature were searched for primary studies of ACT programs with care partners of PLWD. Data were charted and synthesized., Results: Ten studies met inclusion criteria and were analyzed. Amongst these, engagement was highest in three ACT programs that were delivered individually, remotely and were therapist-led or supported. Conversely, engagement was the lowest in two ACT programs that were self-directed, web-based and had minimal or no care partner-therapist interaction. Program factors perceived as influencing engagement included tailoring and personalization, mode of delivery and format, therapeutic support and connectedness, program duration and pace., Conclusion: Findings from this review suggest that care partners engagement may be promoted by designing ACT programs that focus on the therapeutic client-therapist relationship, are delivered remotely and individually. Future research should focus on evaluation of best implementation practices for engagement and effectiveness.
- Published
- 2024
- Full Text
- View/download PDF
10. Raman spectroscopy of brain and skin tissue in a minipig model of Huntington's disease.
- Author
-
Tipatet K, Du Boulay I, Muir H, Davison-Gates L, Ellederová Z, and Downes A
- Subjects
- Animals, Humans, Swine, Swine, Miniature, Spectrum Analysis, Raman, Brain, Huntington Disease diagnosis, Neurodegenerative Diseases
- Abstract
We applied Raman spectroscopy to brain and skin tissues from a minipig model of Huntington's disease. Differences were observed between measured spectra of tissues with and without Huntington's disease, for both brain tissue and skin tissue. There are linked to changes in the chemical composition between tissue types. Using machine learning we correctly classified 96% of test spectra as diseased or wild type, indicating that the test would have a similar accuracy when used as a diagnostic tool for the disease. This suggests the technique has great potential in the rapid and accurate diagnosis of Huntington's and other neurodegenerative diseases in a clinical setting.
- Published
- 2024
- Full Text
- View/download PDF
11. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.
- Author
-
Gobeil P, Pillet S, Boulay I, Charland N, Lorin A, Cheng MP, Vinh DC, Boutet P, Van Der Most R, Roman F, Ceregido MA, Landry N, D'Aoust MA, and Ward BJ
- Subjects
- Adult, Humans, Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines, Immunity, SARS-CoV-2, Spike Glycoprotein, Coronavirus, COVID-19 prevention & control, Vaccines, Virus-Like Particle, Viral Vaccines
- Abstract
As the SARS-CoV-2 pandemic evolves, vaccine evaluation needs to include consideration of both durability and cross-reactivity. This report expands on previously reported results from a Phase 1 trial of an AS03-adjuvanted, plant-based coronavirus-like particle (CoVLP) displaying the spike (S) glycoprotein of the ancestral SARS-CoV-2 virus in healthy adults (NCT04450004). Humoral and cellular responses against the ancestral strain were evaluated 6 months post-second dose (D201) as secondary outcomes. Independent of dose, all vaccinated individuals retain binding antibodies, and ~95% retain neutralizing antibodies (NAb). Interferon gamma and interleukin-4 responses remain detectable in ~94% and ~92% of vaccinees respectively. In post-hoc analyses, variant-specific (Alpha, Beta, Delta, Gamma and Omicron) NAb were assessed at D42 and D201. Using a live virus neutralization assay, broad cross-reactivity is detectable against all variants at D42. At D201, cross-reactive antibodies are detectable in almost all participants against Alpha, Gamma and Delta variants (94%) and the Beta variant (83%) and in a smaller proportion against Omicron (44%). Results are similar with the pseudovirion assay. These data suggest that two doses of 3.75 µg CoVLP+AS03 elicit a durable and cross-reactive response that persists for at least 6 months post-vaccination., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
12. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.
- Author
-
Charland N, Gobeil P, Pillet S, Boulay I, Séguin A, Makarkov A, Heizer G, Bhutada K, Mahmood A, Trépanier S, Hager K, Jiang-Wright J, Atkins J, Saxena P, Cheng MP, Vinh DC, Boutet P, Roman F, Van Der Most R, Ceregido MA, Dionne M, Tellier G, Gauthier JS, Essink B, Libman M, Haffizulla J, Fréchette A, D'Aoust MA, Landry N, and Ward BJ
- Abstract
The rapid spread of SARS-CoV-2 continues to impact humanity on a global scale with rising total morbidity and mortality. Despite the development of several effective vaccines, new products are needed to supply ongoing demand and to fight variants. We report herein a pre-specified interim analysis of the phase 2 portion of a Phase 2/3, randomized, placebo-controlled trial of a coronavirus virus-like particle (CoVLP) vaccine candidate, produced in plants that displays the SARS-CoV-2 spike glycoprotein, adjuvanted with AS03 (NCT04636697). A total of 753 participants were recruited between 25th November 2020 and 24th March 2021 into three groups: Healthy Adults (18-64 years: N = 306), Older Adults (≥65 years: N = 282) and Adults with Comorbidities (≥18 years: N = 165) and randomized 5:1 to receive two intramuscular doses of either vaccine (3.75 µg CoVLP/dose+AS03) or placebo, 21 days apart. This report presents safety, tolerability and immunogenicity data up to 6 months post-vaccination. The immune outcomes presented include neutralizing antibody (NAb) titres as measured by pseudovirion assay at days 21 and 42 as well as neutralizing antibody cross-reactivity to several variants of concern (VOCs): Alpha, Beta, Gamma, Delta, and Omicron (BA.1), up to 201 days post-immunization. Cellular (IFN-γ and IL-4 ELISpot) response data in day 21 and 42 peripheral blood are also presented. In this study, CoVLP+AS03 was well-tolerated and adverse events (AE) after each dose were generally mild to moderate and transient. Solicited AEs in Older Adults and Adults with Comorbidities were generally less frequent than in Healthy Adults and the reactogenicity was higher after the second dose. CoVLP+AS03 induced seroconversion in >35% of participants in each group after the first dose and in ~98% of participants, 21 days after the second dose. In all cohorts, 21-days after the second dose, NAb levels in sera against the vaccine strain were ~10-times those in a panel of convalescent sera. Cross-reactivity to Alpha, Beta and Delta variants was generally retained to day 201 (>80%) while cross-reactivity to the Gamma variant was reduced but still substantial at day 201 (73%). Cross-reactivity to the Omicron variant fell from 72% at day 42 to 20% at day 201. Almost all participants in all groups (>88%) had detectable cellular responses (IFN-γ, IL-4 or both) at 21 days after the second dose. A Th1-biased response was most evident after the first dose and was still present after the second dose. These data demonstrated that CoVLP+AS03 is well-tolerated and highly immunogenic, generating a durable (at least 6 months) immune response against different VOCs, in adults ≥18 years of age, with and without comorbidities., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
13. Renal arteriovenous malformation and venous thrombosis: a tumour-like presentation.
- Author
-
Kosseifi F, Brenier M, Boulay I, and Durand X
- Subjects
- Aged, Female, Humans, Renal Veins diagnostic imaging, Arteriovenous Malformations complications, Arteriovenous Malformations diagnostic imaging, Kidney Neoplasms diagnosis, Kidney Neoplasms diagnostic imaging, Urologic Diseases, Venous Thrombosis diagnostic imaging, Venous Thrombosis etiology
- Abstract
Renal arteriovenous malformation is a primarily congenital renal vascular abnormality. It is usually diagnosed incidentally on imaging, and the most common subtype is 'cirsoid', consisting of multiple, enlarged arterial feeders interconnecting with draining veins. We present a 74-year-old woman with an incidental finding of what was at first considered a hypervascularised kidney tumour but turned out to be a left intrarenal arteriovenous malformation associated with a left renal vein thrombosis. Selective endovascular embolisation was performed. The cause-consequence relationship between the arteriovenous malformation and the thrombosis is unique. To our knowledge, no such case has ever been reported., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
14. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
- Author
-
Ward BJ, Gobeil P, Séguin A, Atkins J, Boulay I, Charbonneau PY, Couture M, D'Aoust MA, Dhaliwall J, Finkle C, Hager K, Mahmood A, Makarkov A, Cheng MP, Pillet S, Schimke P, St-Martin S, Trépanier S, and Landry N
- Subjects
- Adolescent, Adult, Antibodies, Neutralizing blood, Antibodies, Viral blood, COVID-19 genetics, COVID-19 immunology, COVID-19 therapy, COVID-19 virology, COVID-19 Vaccines adverse effects, Canada, Drug-Related Side Effects and Adverse Reactions immunology, Drug-Related Side Effects and Adverse Reactions virology, Female, Humans, Immunization, Passive, Immunogenicity, Vaccine, Male, Middle Aged, SARS-CoV-2 drug effects, SARS-CoV-2 pathogenicity, Spike Glycoprotein, Coronavirus, Vaccines, Virus-Like Particle adverse effects, Young Adult, COVID-19 Serotherapy, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, Drug-Related Side Effects and Adverse Reactions prevention & control, Vaccines, Virus-Like Particle administration & dosage
- Abstract
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds the supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ). The co-primary outcomes were the short-term tolerability/safety and immunogenicity of CoVLP formulations assessed by neutralizing antibody (NAb) and cellular responses. Secondary outcomes in this ongoing study include safety and immunogenicity assessments up to 12 months after vaccination. Adults (18-55 years, n = 180) were randomized at two sites in Quebec, Canada, to receive two intramuscular doses of CoVLP (3.75 μg, 7.5 μg, and 15 μg) 21 d apart, alone or adjuvanted with AS03 or CpG1018. All formulations were well tolerated, and adverse events after vaccination were generally mild to moderate, transient and highest in the adjuvanted groups. There was no CoVLP dose effect on serum NAbs, but titers increased significantly with both adjuvants. After the second dose, NAbs in the CoVLP + AS03 groups were more than tenfold higher than titers in Coronavirus 2019 convalescent sera. Both spike protein-specific interferon-γ and interleukin-4 cellular responses were also induced. This pre-specified interim analysis supports further evaluation of the CoVLP vaccine candidate.
- Published
- 2021
- Full Text
- View/download PDF
15. Imaging protocols for renal multiparametric MRI and MR urography: results of a consensus conference from the French Society of Genitourinary Imaging.
- Author
-
Rouvière O, Cornelis F, Brunelle S, Roy C, André M, Bellin MF, Boulay I, Eiss D, Girouin N, Grenier N, Hélénon O, Lapray JF, Lefèvre A, Matillon X, Ménager JM, Millet I, Ronze S, Sanzalone T, Tourniaire J, Rocher L, and Renard-Penna R
- Subjects
- Female, France, Humans, Male, Consensus, Consensus Development Conferences as Topic, Multiparametric Magnetic Resonance Imaging methods, Societies, Medical, Urinary Tract diagnostic imaging, Urography methods, Urology
- Abstract
Objectives: To develop technical guidelines for magnetic resonance imaging aimed at characterising renal masses (multiparametric magnetic resonance imaging, mpMRI) and at imaging the bladder and upper urinary tract (magnetic resonance urography, MRU)., Methods: The French Society of Genitourinary Imaging organised a Delphi consensus conference with a two-round Delphi survey followed by a face-to-face meeting. Two separate questionnaires were issued for renal mpMRI and for MRU. Consensus was strictly defined using a priori criteria., Results: Forty-two expert uroradiologists completed both survey rounds with no attrition between the rounds. Fifty-six of 84 (67%) statements of the mpMRI questionnaire and 44/71 (62%) statements of the MRU questionnaire reached final consensus. For mpMRI, there was consensus that no injection of furosemide was needed and that the imaging protocol should include T2-weighted imaging, dual chemical shift imaging, diffusion-weighted imaging (use of multiple b-values; maximal b-value, 1000 s/mm
2 ) and fat-saturated single-bolus multiphase (unenhanced, corticomedullary, nephrographic) contrast-enhanced imaging; late imaging (more than 10 min after injection) was judged optional. For MRU, the patients should void their bladder before the examination. The protocol must include T2-weighted imaging, anatomical fast T1/T2-weighted imaging, diffusion-weighted imaging (use of multiple b-values; maximal b-value, 1000 s/mm2 ) and fat-saturated single-bolus multiphase (unenhanced, corticomedullary, nephrographic, excretory) contrast-enhanced imaging. An intravenous injection of furosemide is mandatory before the injection of contrast medium. Heavily T2-weighted cholangiopancreatography-like imaging was judged optional., Conclusion: This expert-based consensus conference provides recommendations to standardise magnetic resonance imaging of kidneys, ureter and bladder., Key Points: • Multiparametric magnetic resonance imaging (mpMRI) aims at characterising renal masses; magnetic resonance urography (MRU) aims at imaging the urinary bladder and the collecting systems. • For mpMRI, no injection of furosemide is needed. • For MRU, an intravenous injection of furosemide is mandatory before the injection of contrast medium; heavily T2-weighted cholangiopancreatography-like imaging is optional.- Published
- 2020
- Full Text
- View/download PDF
16. Imaging protocols for CT urography: results of a consensus conference from the French Society of Genitourinary Imaging.
- Author
-
Renard-Penna R, Rocher L, Roy C, André M, Bellin MF, Boulay I, Eiss D, Girouin N, Grenier N, Hélénon O, Lapray JF, Lefèvre A, Matillon X, Ménager JM, Millet I, Ronze S, Sanzalone T, Tourniaire J, Brunelle S, and Rouvière O
- Subjects
- Contrast Media, Delphi Technique, Diuretics, Furosemide, Humans, Injections, Intravenous, Tomography, X-Ray Computed methods, Urography methods
- Abstract
Objectives: To develop technical guidelines for computed tomography urography., Methods: The French Society of Genitourinary Imaging organised a Delphi consensus conference with a two-round Delphi survey followed by a face-to-face meeting. Consensus was strictly defined using a priori criteria., Results: Forty-two expert uro-radiologists completed both survey rounds with no attrition between the rounds. Ninety-six (70%) of the initial 138 statements of the questionnaire achieved final consensus. An intravenous injection of 20 mg of furosemide before iodinated contrast medium injection was judged mandatory. Improving the quality of excretory phase imaging through oral or intravenous hydration of the patient or through the use of an abdominal compression device was not deemed necessary. The patient should be imaged in the supine position and placed in the prone position only at the radiologist's request. The choice between single-bolus and split-bolus protocols depends on the context, but split-bolus protocols should be favoured whenever possible to decrease patient irradiation. Repeated single-slice test acquisitions should not be performed to decide of the timing of excretory phase imaging; instead, excretory phase imaging should be performed 7 min after the injection of the contrast medium. The optimal combination of unenhanced, corticomedullary phase and nephrographic phase imaging depends on the context; suggestions of protocols are provided for eight different clinical situations., Conclusion: This expert-based consensus conference provides recommendations to standardise the imaging protocol for computed tomography urography., Key Points: • To improve excretory phase imaging, an intravenous injection of furosemide should be performed before the injection of iodinated contrast medium. • Systematic oral or intravenous hydration is not necessary to improve excretory phase imaging. • The choice between single-bolus and split-bolus protocols depends on the context, but split-bolus protocols should be favoured whenever possible to decrease patient irradiation.
- Published
- 2020
- Full Text
- View/download PDF
17. 12th GCC Closed Forum: critical reagents; oligonucleotides; CoA; method transfer; HRMS; flow cytometry; regulatory findings; stability and immunogenicity.
- Author
-
Briscoe C, Hughes N, Hayes R, Islam R, Bennett P, Stouffer B, Cape S, Rhyne P, Beaver C, Charles JS, Kakkanaiah V, Xu A, Caturla MC, Spriggs F, Tayyem R, Barry C, Keyhani A, Zimmer J, Couerbe P, Warren M, Khadang A, Bourdage J, Lindley K, Williams D, Sheldon C, Satterwhite C, Vija J, Yu M, Boulay I, Stamatopoulos J, Lin J, Estdale S, Thomas E, Dinan A, MacNeill R, Xiao YQ, Matassa L, Garofolo W, Savoie N, Hristopoulos G, Xu A, Goodwin L, Awaiye K, Ritzén H, Bouhajib M, Marco CD, Savu SR, Nehls C, Tabler E, Hays A, Karnik S, Brown M, Lowes S, DuBey I, Kulagina N, Lindsay J, Williard C, Wang H, Malone M, Wells E, Fang X, and Moussallie M
- Subjects
- Indicators and Reagents chemistry, Certification, Chemistry Techniques, Analytical, Flow Cytometry, Mass Spectrometry, Oligonucleotides analysis, Social Control, Formal, Societies, Scientific
- Abstract
The 12th GCC Closed Forum was held in Philadelphia, PA, USA, on 9 April 2018. Representatives from international bioanalytical Contract Research Organizations were in attendance in order to discuss scientific and regulatory issues specific to bioanalysis. The issues discussed at the meeting included: critical reagents; oligonucleotides; certificates of analysis; method transfer; high resolution mass spectrometry; flow cytometry; recent regulatory findings and case studies involving stability and nonclinical immunogenicity. Conclusions and consensus from discussions of these topics are included in this article.
- Published
- 2019
- Full Text
- View/download PDF
18. Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis.
- Author
-
Islam R, Kar S, Ritzén H, Hays A, Tayyem R, Barry C, Keyhani A, Zimmer J, Cruz Caturla M, Couerbe P, Warren M, Khadang A, Bourdage J, Lindley K, Williams D, Hughes N, Sheldon C, Satterwhite C, Vija J, Yu M, Boulay I, Stamatopoulos J, Lin J, Cape S, Estdale S, Thomas E, Dinan A, MacNeill R, Xiao YQ, Garofolo W, Savoie N, Brown M, Rhyne P, Hristopoulos G, Xu A, Goodwin L, Spriggs F, Xu A, Awaiye K, Hayes R, St Charles J, Bouhajib M, DiMarco C, DiMarco L, Savu SR, Bennett P, Kakkanaiah V, Nehls C, Stouffer B, Tabler E, Briscoe C, Karnik S, DuBey I, Kulagina N, Lindsay J, Beaver C, Williard C, Wang H, Feng H, Malone M, Wells E, Fang X, and Moussallie M
- Subjects
- Biological Assay standards, Drug Discovery, Humans, Ligands, Pharmaceutical Preparations chemistry, Pharmaceutical Preparations metabolism, Pharmaceutical Preparations standards, Quality Control, Reagent Kits, Diagnostic, Reference Standards, Societies, Pharmaceutical, Surveys and Questionnaires, Biological Assay methods, Biomarkers analysis
- Abstract
Over the last decade, the use of biomarker data has become integral to drug development. Biomarkers are not only utilized for internal decision-making by sponsors; they are increasingly utilized to make critical decisions for drug safety and efficacy. As the regulatory agencies are routinely making decisions based on biomarker data, there has been significant scrutiny on the validation of biomarker methods. Contract research organizations regularly use commercially available immunoassay kits to validate biomarker methods. However, adaptation of such kits in a regulated environment presents significant challenges and was one of the key topics discussed during the 12th Global Contract Research Organization Council for Bioanalysis (GCC) meeting. This White Paper reports the GCC members' opinion on the challenges facing the industry and the GCC recommendations on the classification of commercial kits that can be a win-win for commercial kit vendors and end users.
- Published
- 2019
- Full Text
- View/download PDF
19. [Salvage cryotherapy of prostate cancer after failed external radiotherapy and brachytherapy: Morbidity and mid-term oncological results].
- Author
-
Gevorgyan A, Hétet JF, Robert M, Duchattelle-Dussaule V, Corno L, Boulay I, and Baumert H
- Subjects
- Brachytherapy adverse effects, Disease-Free Survival, Feasibility Studies, Follow-Up Studies, France, Humans, Male, Neoplasm Grading, Prostatic Neoplasms blood, Prostatic Neoplasms therapy, Retrospective Studies, Risk Factors, Treatment Outcome, Biomarkers, Tumor blood, Cryosurgery methods, Prostate-Specific Antigen blood, Prostatic Neoplasms diagnosis, Prostatic Neoplasms surgery, Radiotherapy adverse effects, Salvage Therapy methods
- Abstract
Objective: To study the oncologic and functional results of salvage cryotherapy after failure of external radiotherapy and brachytherapy., Materials and Methods: Patients treated by total salvage cryotherapy (3rd generation) in 2 centers (Groupe Hospitalier Saint-Joseph in Paris and Clinique Jule-Verne Nantes) in between January 2008 and April 2016 were included. The biochemical recurrence-free survival (BRFS) was calculated using the Phoenix criteria (PSA>nadir+2ng/mL). The functional results were assessed clinically., Results: Ninety-seven patients with an average follow up of 39.4months were evaluated retrospectively. The 5-year biochemical recurrence-free survival (5y-BRFS) among all patients was 58.1% (IC à 95% [45.9-68.5]). Low and intermediate risk patients (d'Amico classification) were less prone to biochemical recurrence than high risk (81.05% (IC à 95% [64.1-90.5]) 5y-BRFS as opposed to 35.09% (IC à 95% [20.1-50.4]) respectively) (P<0.0001). As were patients with a Gleason score≤7 75.35% (IC à 95% [59.7-85.6]) compared to 32.31% (IC à 95% [16.5-49.2]) for higher Gleason (>7 scores [P=0.0002]). A Gleason score>7 (OR=6.9; P=0.002), PSA nadir>1ng/mL (OR=25.8; P=0.0026) and peri-urethral invasion (OR=35.8; P<0.001) were major risk factors for local recurrence in univariate analysis. In multivariate analysis, only PSA nadir>1ng/mL (OR=12.9; P=0.042) and peri-urethral invasion (OR=21.6; P=0.0003) remain major risk factors for recurrence. About 13 (16.46%) patients were incontinent of which 3 (3.79%) required placement of an artificial urinary sphincter. Erectile dysfunction was present in 66 (83.5%) patients. Recto-urethral fistula was uncommon in 1 patient (1.27%)., Conclusion: Salvage cryotherapy after failure of external radiotherapy and brachytherapy is a reliable and reproducible technique with promising oncological and functional results. Study of prognostic factors will help better select eligible patients in the future., Level of Evidence: 4., (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
20. Thrombospondin-1 (TSP-1), a new bone morphogenetic protein-2 and -4 (BMP-2/4) antagonist identified in pituitary cells.
- Author
-
Sallon C, Callebaut I, Boulay I, Fontaine J, Logeart-Avramoglou D, Henriquet C, Pugnière M, Cayla X, Monget P, Harichaux G, Labas V, Canepa S, and Taragnat C
- Subjects
- Animals, Animals, Inbred Strains, Bone Morphogenetic Protein 2 blood, Bone Morphogenetic Protein 2 genetics, Bone Morphogenetic Protein 2 metabolism, Bone Morphogenetic Protein 4 blood, Bone Morphogenetic Protein 4 genetics, Bone Morphogenetic Protein 4 metabolism, Cell Line, Cells, Cultured, Computational Biology, Female, Genes, Reporter, Humans, Mice, Pituitary Gland cytology, Protein Interaction Domains and Motifs, Recombinant Fusion Proteins chemistry, Recombinant Fusion Proteins isolation & purification, Recombinant Fusion Proteins metabolism, Recombinant Proteins chemistry, Recombinant Proteins metabolism, Sequence Homology, Amino Acid, Sheep, Domestic, Thrombospondin 1 chemistry, Thrombospondin 1 isolation & purification, Bone Morphogenetic Protein 2 antagonists & inhibitors, Bone Morphogenetic Protein 4 antagonists & inhibitors, Models, Molecular, Pituitary Gland metabolism, Response Elements, Thrombospondin 1 metabolism
- Abstract
Bone morphogenetic proteins (BMPs) regulate diverse cellular responses during embryogenesis and in adulthood including cell differentiation, proliferation, and death in various tissues. In the adult pituitary, BMPs participate in the control of hormone secretion and cell proliferation, suggesting a potential endocrine/paracrine role for BMPs, but some of the mechanisms are unclear. Here, using a bioactivity test based on embryonic cells (C3H10T1/2) transfected with a BMP-responsive element, we sought to determine whether pituitary cells secrete BMPs or BMP antagonists. Interestingly, we found that pituitary-conditioned medium contains a factor that inhibits action of BMP-2 and -4. Combining surface plasmon resonance and high-resolution mass spectrometry helped pinpoint this factor as thrombospondin-1 (TSP-1). Surface plasmon resonance and co-immunoprecipitation confirmed that recombinant human TSP-1 can bind BMP-2 and -4 and antagonize their effects on C3H10T1/2 cells. Moreover, TSP-1 inhibited the action of serum BMPs. We also report that the von Willebrand type C domain of TSP-1 is likely responsible for this BMP-2/4-binding activity, an assertion based on sequence similarity that TSP-1 shares with the von Willebrand type C domain of Crossveinless 2 (CV-2), a BMP antagonist and member of the chordin family. In summary, we identified for the first time TSP-1 as a BMP-2/-4 antagonist and presented a structural basis for the physical interaction between TSP-1 and BMP-4. We propose that TSP-1 could regulate bioavailability of BMPs, either produced locally or reaching the pituitary via blood circulation. In conclusion, our findings provide new insights into the involvement of TSP-1 in the BMP-2/-4 mechanisms of action., (© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
21. Feasibility of nephron-sparing surgery in giant oncocytoma.
- Author
-
Hajj AE, Thanigasalam R, Boulay I, Molinié V, Escudier B, and Baumert H
- Abstract
Oncocytomas represent 3 to 7% of renal masses and behave as benign tumours. Nephron-sparing procedures are preferred for biopsy confirmed lesions; however, giant oncocytomas have been generally treated by radical nephrectomy. We report the first case of partial nephrectomy in a 45-year-old man who presented with a 20-cm oncocytoma. At the 1 year follow-up, he had a normal functioning kidney. Despite the difficulty of this procedure, partial nephrectomy for very large benign tumours can be considered in appropriately selected young patients.
- Published
- 2014
- Full Text
- View/download PDF
22. Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats.
- Author
-
Chakrabarty R, Tran H, Boulay I, Moran T, Parenteau A, Tavcar R, Bigras M, Hagerman A, Serl S, Thompson B, and Coffey M
- Subjects
- Animals, Female, Infusions, Intravenous, Male, Rats, Rats, Sprague-Dawley, Tissue Distribution, Oncolytic Viruses, RNA, Viral analysis, Reoviridae
- Abstract
Numerous pre-clinical and clinical studies on reovirus have generated valuable information which supports the use of this orphan virus as an investigational drug for cancer treatment. Reolysin® (pelareorep) is a clinical formulation of the human Reovirus Type 3 Dearing strain. The clinical safety and efficacy of Reolysin® in humans is being tested on an assortment of cancer indications as a mono and/or combination therapy. Reovirus has many inherent characteristics that make it a potential candidate for virotherapy, including: the rapid and natural spread through the haematogenous route, the ability to overcome immunological barriers thereby reaching tumor sites, and being replication-competent. The purpose of this study was to elucidate the bio-distribution pattern of Reolysin® in healthy Sprague-Dawley rats. Following a single 15-min intravenous infusion via the tail vein in Sprague-Dawley rats, the levels of virus genome were determined in 16 organs/tissues by RT-qPCR (Reverse Transcriptase- Quantitative Polymerase Chain Reaction) over a 336 h (Day 15) incubation regime. Consistent with previous studies, maximal reovirus RNA levels were observed in the spleen; indicating its involvement in viral uptake and clearance, followed by heart, ovaries, tail (infusion site), liver and lungs. All the organs/tissues demonstrated unquantifiable levels of reovirus genome at the end of incubation, suggesting substantial to complete viral clearance. Several studies in the last decade have described the use of reovirus for treating ovarian cancers. An increase of reovirus genome in ovaries at 24 h post infection was noted. The results will aid in the design of additional exploratory clinical trials for Reolysin®.
- Published
- 2013
- Full Text
- View/download PDF
23. Phosphotyrosine binding-mediated oligomerization of downstream of tyrosine kinase (Dok)-1 and Dok-2 is involved in CD2-induced Dok phosphorylation.
- Author
-
Boulay I, Némorin JG, and Duplay P
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Adaptor Proteins, Signal Transducing physiology, Amino Acid Substitution, DNA-Binding Proteins genetics, DNA-Binding Proteins physiology, Down-Regulation physiology, Humans, Jurkat Cells, Mutation, Phosphoproteins genetics, Phosphoproteins physiology, Phosphorylation, Phosphotyrosine physiology, Protein Structure, Tertiary, RNA-Binding Proteins genetics, RNA-Binding Proteins physiology, Tyrosine genetics, Tyrosine metabolism, Adaptor Proteins, Signal Transducing metabolism, CD2 Antigens physiology, DNA-Binding Proteins metabolism, Phosphoproteins metabolism, Phosphotyrosine metabolism, RNA-Binding Proteins metabolism
- Abstract
To date, five members of the downstream of tyrosine kinase (Dok) family have been characterized. In T cells, two members, Dok-1 and Dok-2, are expressed. CD2 or CD28 stimulation, but not CD3/TCR stimulation, induces Dok phosphorylation. Recent evidence suggests that they act as negative regulators of the CD2 and CD28 signaling pathways. To identify the molecular mechanisms involved in Dok-mediated inhibition, we have identified proteins that bind to the phosphotyrosine-binding (PTB) domain of Dok-1 and Dok-2. We showed that the Dok PTB domain mediates phosphotyrosine-dependent homotypic and heterotypic interactions of Dok-1 and Dok-2. Moreover, in CD2-stimulated Jurkat cells, Dok-1 coimmunoprecipitates with tyrosine-phosphorylated Dok-2. To study the involvement of PTB-mediated oligomerization in Dok function, we have generated Jurkat clones overexpressing Dok-1 or Dok-2 with a mutation that prevents oligomerization (in either the PTB domain or Tyr146 of Dok-1 and Tyr139 of Dok-2). These mutations abrogate CD2-induced phosphorylation and the ability of Dok-1 or Dok-2 to inhibit CD2-induced ERK1/2 and NFAT activation. Moreover, overexpression of Dok-1Y146F or Dok-2Y139F interferes with CD2-induced phosphorylation of endogenous Dok, whereas overexpression of PTB mutant or wild-type Dok does not. Taken together, these data indicate that PTB-mediated oligomerization of Dok-1 and Dok-2 represents an essential step for Dok phosphorylation and function.
- Published
- 2005
- Full Text
- View/download PDF
24. Ureteral calculi: diagnostic efficacy of helical CT and implications for treatment of patients.
- Author
-
Boulay I, Holtz P, Foley WD, White B, and Begun FP
- Subjects
- Acute Disease, Adult, Aged, Colic diagnostic imaging, Evaluation Studies as Topic, Female, Follow-Up Studies, Humans, Kidney Diseases diagnostic imaging, Male, Middle Aged, Retrospective Studies, Stents, Tomography, X-Ray Computed instrumentation, Tomography, X-Ray Computed statistics & numerical data, Ureter diagnostic imaging, Ureteral Calculi therapy, Tomography, X-Ray Computed methods, Ureteral Calculi diagnostic imaging
- Abstract
Objective: The purpose of this study was to evaluate whether unenhanced helical CT of the abdomen and pelvis, supplemented as necessary with delayed enhanced CT of the pelvis, is sufficient for urologists to treat patients with acute renal colic., Materials and Methods: CT scans from 99 patients were analyzed retrospectively for the presence, size, and location of ureteral calculi and the presence and severity of secondary signs of obstruction. Clinical follow-up was analyzed by reviewing charts, directly communicating with patients, and reviewing surgical reports. Clinical information was correlated with CT findings., Results: The findings of 51 CT scans were positive for calculi, and the findings of 48 were negative for calculi. The findings from two CT scans were false-positive, and none of the findings were false-negative. The sensitivity, specificity, and accuracy of helical CT were 100%, 96%, and 98%, respectively. A significant difference in stone size was found between patients who were treated conservatively (3.3 +/- 1.3 mm) and patients who underwent a urologic procedure (7 +/- 6.2 mm) (p < .01) and between patients in whom successful ureteral stent placement was the sole intervention (3.9 +/- 2.8 mm) and patients in whom initial stent placement failed and who then underwent a second urologic procedure (7.4 +/- 3 mm) (p < .05). We found no statistically significant difference between the conservatively and interventionally treated groups with respect to stone location. The presence and severity of secondary signs of obstruction were not significantly different between the two groups., Conclusion: Stone size alone was found to correlate with patient treatment. Stone location and the presence and severity of secondary signs of obstruction did not affect patient treatment. Because the degree of obstruction and relative renal function are not relevant to the initial treatment of patients with ureteral stone obstruction, CT is adequate for both diagnosis and treatment.
- Published
- 1999
- Full Text
- View/download PDF
25. [Umbilical metastasis of an endometrial adenocarcinoma: "Sister (Mary) Joseph's nodule". Review of the literature].
- Author
-
Poncelet C, Bouret JM, Boulay I, Tsatsaris V, Ferrand J, Mintz JP, and Ravina JH
- Subjects
- Biopsy, Diagnosis, Differential, Female, Humans, Middle Aged, Prognosis, Skin Neoplasms surgery, Tomography, X-Ray Computed, Adenocarcinoma pathology, Endometrial Neoplasms pathology, Skin Neoplasms secondary, Umbilicus
- Abstract
In the beginning of the XXth century, Sir Hamilton Bailey proposed the name "Sister Joseph's nodule" for the umbilical metastasis of an abdominal cancer. This unusual pathology has multiple primitive etiologies. We report here the 27th case of an umbilical metastasis of an endometrial adenocarcinoma. In case of a malignant umbilical tumor, 75% correspond to a "Sister Joseph's nodule". Their clinical manifestations are quite similar. This secondary localisation could appear before, during or after the diagnosis of the primitive tumor. Adenocarcinoma is the frequently diagnosed histological type. The endometrial origin represents only 1.4% of the cases. Multiple routes of spread exist. Prognosis remains poor. Medico-surgical treatment, in a curative target, will be aggressive and should be adapted at every case. Our case-report recalls a new patho-physiological approach. The extended follow-up of this patient, without further medical treatment, is an additional argument.
- Published
- 1996
26. Tibial artery thrombosis due to varicella zoster virus in a transplant recipient under cyclosporine.
- Author
-
Farge D, Ribaud P, Boulay I, Scrobohaci ML, Rouffy J, and Gluckman E
- Subjects
- Adult, Arteritis microbiology, Chickenpox immunology, Female, Humans, Immunocompromised Host, Bone Marrow Transplantation immunology, Chickenpox complications, Cyclosporine therapeutic use, Thrombosis etiology, Tibial Arteries
- Published
- 1993
27. [Tendinopathy caused by ciprofloxacin with possible partial rupture of Achilles tendon].
- Author
-
Boulay I, Farge D, Haddad A, Bourrier P, Chanu B, and Rouffy J
- Subjects
- Humans, Male, Middle Aged, Rupture, Spontaneous, Achilles Tendon, Ciprofloxacin adverse effects, Spondylitis, Ankylosing chemically induced
- Published
- 1993
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.